New York State Common Retirement Fund Sells 7,700 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

New York State Common Retirement Fund cut its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 16.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 39,939 shares of the biotechnology company’s stock after selling 7,700 shares during the quarter. New York State Common Retirement Fund’s holdings in Axon Enterprise were worth $15,960,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Axon Enterprise by 2.7% in the first quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock valued at $2,547,878,000 after acquiring an additional 212,401 shares during the last quarter. Motley Fool Asset Management LLC boosted its position in shares of Axon Enterprise by 238.7% during the first quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock worth $153,981,000 after purchasing an additional 346,838 shares in the last quarter. 1832 Asset Management L.P. boosted its position in shares of Axon Enterprise by 44.0% during the second quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company’s stock worth $110,546,000 after purchasing an additional 114,800 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Axon Enterprise by 13.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company’s stock worth $108,496,000 after purchasing an additional 45,049 shares in the last quarter. Finally, Thrivent Financial for Lutherans boosted its position in shares of Axon Enterprise by 1.6% during the second quarter. Thrivent Financial for Lutherans now owns 270,430 shares of the biotechnology company’s stock worth $79,571,000 after purchasing an additional 4,365 shares in the last quarter. 79.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

AXON has been the topic of a number of recent analyst reports. Needham & Company LLC lifted their price target on shares of Axon Enterprise from $400.00 to $525.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Craig Hallum lifted their price target on shares of Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Bank of America initiated coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $380.00 price target on the stock. The Goldman Sachs Group lifted their price target on shares of Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Finally, Northland Securities raised their price objective on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $392.85.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CFO Brittany Bagley sold 4,338 shares of Axon Enterprise stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $378.95, for a total value of $1,643,885.10. Following the sale, the chief financial officer now directly owns 98,825 shares in the company, valued at approximately $37,449,733.75. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Brittany Bagley sold 4,338 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the transaction, the chief financial officer now directly owns 98,825 shares in the company, valued at $37,449,733.75. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Matthew R. Mcbrady sold 2,000 shares of the business’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $364.66, for a total transaction of $729,320.00. Following the transaction, the director now owns 4,892 shares in the company, valued at $1,783,916.72. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 371,172 shares of company stock worth $137,000,162. Insiders own 5.70% of the company’s stock.

Axon Enterprise Stock Up 2.2 %

Shares of AXON stock opened at $441.09 on Wednesday. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. Axon Enterprise, Inc. has a 1 year low of $212.88 and a 1 year high of $455.17. The firm’s fifty day moving average price is $403.76 and its two-hundred day moving average price is $342.09. The firm has a market capitalization of $33.33 billion, a P/E ratio of 116.38, a PEG ratio of 10.84 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The firm had revenue of $504.00 million for the quarter, compared to analyst estimates of $478.35 million. During the same period in the previous year, the business earned $0.80 EPS. The company’s revenue was up 34.5% compared to the same quarter last year. On average, equities analysts predict that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.